Production of highly specific monoclonal antibodies to monensin and development of a microELISA to detect this antibiotic

Pauillac, Serge; Halmos, Thérèse; Labrousse, H.; Antonakis, Kostas; Avraméas, Stratis

doi:10.1016/0022-1759(93)90309-u

Cited by 12 publications

(20 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1989, the elucidation of the structure of the main congener P-CTX-1B revealed that the only functional group available was a primary hydroxyl located on a 4-C side chain of ring A [ 216 ]. In this context, our initial immunochemical knowledge of CTXs mainly came from experiments performed with more available hydroxylated polyether compounds, such as PbTxs [ 217 – 221 ], monensin [ 222 ], or even cholesterol [ 223 ]. Such experiments required a three-step procedure: (i) the formation of a hemisuccinate derivative of these hydroxylated haptens; (ii) the activation of the newly formed carboxyl group; and (iii) the conjugation to the protein.…”

Section: Methodologies For Ctxs Determinationmentioning

confidence: 99%

Update on Methodologies Available for Ciguatoxin Determination: Perspectives to Confront the Onset of Ciguatera Fish Poisoning in Europe

et al. 2010

Self Cite

View full text Add to dashboard Cite

Ciguatera fish poisoning (CFP) occurs mainly when humans ingest finfish contaminated with ciguatoxins (CTXs). The complexity and variability of such toxins have made it difficult to develop reliable methods to routinely monitor CFP with specificity and sensitivity. This review aims to describe the methodologies available for CTX detection, including those based on the toxicological, biochemical, chemical, and pharmaceutical properties of CTXs. Selecting any of these methodological approaches for routine monitoring of ciguatera may be dependent upon the applicability of the method. However, identifying a reference validation method for CTXs is a critical and urgent issue, and is dependent upon the availability of certified CTX standards and the coordinated action of laboratories. Reports of CFP cases in European hospitals have been described in several countries, and are mostly due to travel to CFP endemic areas. Additionally, the recent detection of the CTX-producing tropical genus Gambierdiscus in the eastern Atlantic Ocean of the northern hemisphere and in the Mediterranean Sea, as well as the confirmation of CFP in the Canary Islands and possibly in Madeira, constitute other reasons to study the onset of CFP in Europe [1]. The question of the possible contribution of climate change to the distribution of toxin-producing microalgae and ciguateric fish is raised. The impact of ciguatera onset on European Union (EU) policies will be discussed with respect to EU regulations on marine toxins in seafood. Critical analysis and availability of methodologies for CTX determination is required for a rapid response to suspected CFP cases and to conduct sound CFP risk analysis.

show abstract

Section: Methodologies For Ctxs Determinationmentioning

confidence: 99%

Update on Methodologies Available for Ciguatoxin Determination: Perspectives to Confront the Onset of Ciguatera Fish Poisoning in Europe

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…These include an LC with fluorescent detection method for beef liver outlined by Martinez and Shimoda, 2 a TLC-bioautography technique for use with poultry tissues as described by VanderKop and MacNeil 3 and more recently the LC-MS method, suitable for both poultry muscle and liver, of Blanchflower and Kennedy. 4 Workers have also previously reported the development of immunoassay techniques for the detection of monensin, however Paulliac et al 5 did not apply the immunoassay developed to biological material while Mount and Failla 6 analysed only spiked urine, serum and faeces. To date few researchers have described the use of immunoassays in incurred tissue residue analysis.…”

mentioning

confidence: 99%

Detection of Monensin Residues in Poultry Liver Using an Enzyme Immunoassay

Crooks¹,

Traynor²,

Elliott³

et al. 1997

Analyst

View full text Add to dashboard Cite

Monensin, a carboxylic acid ionophore, is commonly fed to poultry to control coccidiosis. A method for the detection and quantification of monensin residues in liver has been developed. Samples (3 g) were extracted with acetonitrile-water and applied to a competitive enzyme immunoassay using a polyclonal antiserum raised against a monensin-transferrin conjugate. The limit of detection (mean + 3s) calculated from the analysis of 12 known negative samples was 2.91 ng g 21 . Intra-and inter-assay RSD were determined as 8.5 and 10.6%, respectively, using a liver sample fortified with 20 ng g 21 monensin. A pharmacokinetic study in which 70 six week old broilers were fed monensin at a rate of 120 mg kg 21 in their feed for 14 d resulted in mean monensin liver residues of 102 ng g 21 . However these had fallen below the limit of detection of the assay within the 3 d withdrawal period recommended by the manufacturer.

show abstract

“…1) Preparation of the immunogen (compound 5). Compound 4 was coupled to KLH by a modified mixed anhydride reaction (13,14,36,39). The 5'-O-hemisuccinate of FIAU (compound 4) (60 mg, 0.127 mmol) was dissolved in 0.68 ml of ice-cold, dry DMF in a silanized 12-by-75-mm borosilicate glass tube.…”

mentioning

confidence: 99%

Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers

Bowsher

Compton

Kirkwood

et al. 1994

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Fialuridine (FIAU) is a halogen-substituted analog of thymidine that was undergoing clinical investigation as a drug for the treatment of chronic hepatitis B viral infection. However, clinical trials of FIAU were terminated after adverse events occurred following chronic oral administration. Prior to the termination of clinical trials, a sensitive assay was needed for the measurement of FIAU because of the anticipated low dose administered to patients. We therefore undertook the development of a radioimmunoassay (RIA). A specific antiserum was raised in rabbits following immunization with a 5'-O-hemisuccinate analog of FIAU coupled to keyhole limpet hemocyanin. Radiolabeled FIAU was synthesized by a destannylation procedure by using sodium [125j]iodide. We developed a competitive-binding procedure and used precipitation with polyethylene glycol as the method for separating the bound and free forms of FIAU. The RIA is sensitive (0.2 ng/ml), specific (negligible interference from known metabolites and endogenous nucleosides), and reproducible (interassay coeflicients of variation range from 5 to 19.7% for serum controls). We used the RIA to assess the pharmacokinetics of FIAU in healthy adult volunteers following administration of a single 5-mg oral dose. The sensitivity of the RIA permitted the detection of a prolonged elimination phase for FIAU in healthy volunteers and dogs, with mean elimination half-lives of 29.3 and 35.3 h, respectively. We conclude the RIA is a valid method for the quantification of FIAU in biological fluids.Fialuridine (FIAU), 1-(2'-deoxy-2'-fluoro-13-D-arabinofuranosyl)-5-iodouracil (Fig. 1, compound 2), is one of a series of 2'-fluoro-substituted arabinosyl pyrimidine nucleosides that have demonstrated potent antiviral activities against a number of clinically important viruses, including hepatitis B virus (HBV) (7,11,28,47). Analogs of FIAU have been shown to inhibit viral replication in the woodchuck and duck models of HBV infection (18,19). Although the mechanism of the anti-HBV activity is not well understood, evidence suggests that the triphosphate analog of FIAU is a potent inhibitor of HBV DNA polymerase activity (17,23,43). During early clinical investigation FIAU showed much promise as an anti-HBV drug because it markedly reduced the level of HBV DNA in the serum of patients with chronic hepatitis B (20). However, clinical trials were terminated after adverse events occurred following oral administration of FIAU (0.1 and 0.25 mg/kg of body weight per day) for more than 2 months (24, 29). The mechanism of the unexpected delayed toxicity is unresolved.Prior to the termination of clinical trials an assay was needed to quantify FIAU in biological fluids. However, the anticipated low therapeutic dose in patients necessitated the development of a highly sensitive analytical method. The criterion of sensitivity precluded the use of an existing UV-based high-pressure liquid chromatographic (HPLC) method for FIAU because its

show abstract

Production of highly specific monoclonal antibodies to monensin and development of a microELISA to detect this antibiotic

Cited by 12 publications

References 18 publications

Update on Methodologies Available for Ciguatoxin Determination: Perspectives to Confront the Onset of Ciguatera Fish Poisoning in Europe

Update on Methodologies Available for Ciguatoxin Determination: Perspectives to Confront the Onset of Ciguatera Fish Poisoning in Europe

Detection of Monensin Residues in Poultry Liver Using an Enzyme Immunoassay

Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers

Contact Info

Product

Resources

About